You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug SYNTHROID


✉ Email this page to a colleague

« Back to Dashboard


Company Tradename Ingredient NDC Excipient Potential Generic Entry
AbbVie Inc SYNTHROID levothyroxine sodium 0074-4341 ACACIA
AbbVie Inc SYNTHROID levothyroxine sodium 0074-4341 FD&C YELLOW NO. 6
AbbVie Inc SYNTHROID levothyroxine sodium 0074-4341 LACTOSE MONOHYDRATE
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Excipient Strategy and Commercial Opportunities for SYNTHROID

Last updated: February 28, 2026

What is SYNTHROID and What Role Do Excipients Play?

SYNTHROID (levothyroxine sodium) is a synthetic thyroid hormone used primarily to treat hypothyroidism. It requires a stable, bioavailable formulation to ensure consistent absorption and efficacy. Excipients are inactive ingredients in the drug formulation that influence stability, dissolution, bioavailability, and shelf life.

Stability and bioavailability are crucial for levothyroxine products due to its sensitivity to environmental factors such as temperature, pH, and light. Selecting appropriate excipients is paramount to optimize these parameters, reduce variability, and extend shelf life.

What Are the Common Excipients Used in SYNTHROID Formulations?

The formulation of SYNTHROID typically includes:

  • Binders: Microcrystalline cellulose maintains tablet integrity.
  • Disintegrants: Croscarmellose sodium improves tablet breakup, aiding dissolution.
  • Fillers/Diluents: Lactose monohydrate adds bulk.
  • Lubricants: Magnesium stearate prevents sticking during compression.
  • Preservatives: No preservatives are commonly used, but certain formulations may incorporate antioxidants.
  • Flavoring agents: Not generally applicable due to oral tablet form.

Excipients are selected for their inert nature, compatibility with active ingredients, and ability to maintain chemical stability under storage conditions.

How Do Excipient Strategies Impact Bioavailability and Stability?

In levothyroxine formulations, excipients affect:

  • Chemical stability: Antioxidants like ascorbic acid can prevent oxidation.
  • Dissolution profile: Disintegrants influence how quickly the drug releases in vivo.
  • Absorption consistency: Excipients influence gastric pH and transit time, impacting absorption variability.

Optimizing excipients addresses issues such as low bioavailability and inconsistent absorption, which are associated with certain formulations and patient populations.

What Are the Commercial Opportunities from Excipient Optimization?

  1. Enhanced Bioavailability Formulations: New excipient combinations can improve absorption, reducing dose variability and enhancing clinical efficacy. For example, employing disintegrants that activate in specific pH environments may offer better performance.

  2. Extended Shelf Life: Incorporating antioxidants or stabilizers protects against oxidation and hydrolysis, expanding the product’s shelf life and reducing waste.

  3. Biopharmaceutical Classifications Improvements: Formulations with optimized excipients can shift the drug's classification within the Biopharmaceutics Classification System (BCS) from class III to class I, enabling more flexible regulatory pathways.

  4. Differentiation through Novel Delivery Forms: Development of alternative formulations—such as orodispersible tablets, liquid suspensions, or novel dosage forms—relies heavily on excipient innovation to improve patient compliance.

  5. Late-Stage Formulation Innovations: Patent-protected excipient combinations can serve as barriers to generic entry, enabling premium pricing.

  6. Regulatory Advantage: Selecting excipients with well-characterized safety profiles simplifies regulatory approval, especially for biosimilar versions or reformulations.

  7. Supply Chain Optimization: Sourcing excipients with improved stability, cost-effectiveness, or supply security can enhance profitability and mitigate risks associated with raw material shortages.

What Are Key Considerations for Excipient Strategy Development?

  • Compatibility with levothyroxine's chemical stability.
  • Regulatory acceptance, including GRAS (Generally Recognized As Safe) status.
  • Impact on manufacturing processes.
  • Patient-specific factors, such as allergies or sensitivities.
  • Cost implications; excipients should not significantly increase manufacturing costs unless justified by added value.

What Are the Regulatory and Market Trends Related to Excipient Use?

  • Increasing focus on excipient transparency in labeling.
  • Growing demand for gluten-free, allergen-free excipients.
  • Regulations favoring excipients with established safety and stability profiles.
  • The rise of personalized medicine prompting formulations tailored to specific patient needs.

Summary Table of Excipient Impact Factors

Factor Influence Market Implication
Stability Enhancers Extend shelf life, improve storage conditions Reduced waste, longer distribution range
Dissolution Modifiers Improve absorption consistency Better efficacy, increased patient adherence
Compatibility Prevent interactions affecting drug stability Regulatory compliance, reduced rejections
Cost and Supply Chain Control manufacturing costs and supply risks Competitive pricing, consistent supply

Final Assessment

Optimizing excipient selections in SYNTHROID formulations can deliver improved bioavailability, stability, and patient compliance. Such innovations enable differentiation, support regulatory strategies, and open avenues for premium formulations or new delivery systems.


Key Takeaways

  • Excipients are critical for maintaining the stability, bioavailability, and shelf life of SYNTHROID.
  • Innovative excipient strategies can address absorption variability, shelf stability, and patent life.
  • New formulations can underpin premium pricing, regulatory advantages, and differentiation.
  • Supply chain and regulatory considerations influence excipient selection.
  • There are opportunities for reformulations, novel delivery forms, and personalized solutions driven by excipient innovation.

FAQs

Q1. How does excipient selection impact levothyroxine's absorption?
It influences dissolution and transit time in the gastrointestinal tract, affecting absorption uniformity and consistency.

Q2. What excipients can improve SYNTHROID’s shelf life?
Antioxidants like ascorbic acid can mitigate oxidation; stabilizers may reduce hydrolysis.

Q3. Are there regulatory hurdles associated with excipient changes in SYNTHROID?
Yes. Changes must demonstrate bioequivalence and safety, especially if excipients differ significantly from the approved formulation.

Q4. Can excipient innovation reduce manufacturing costs?
Potentially, if new excipients enable simplified manufacturing processes or reduce waste, but initial R&D costs may offset savings.

Q5. What delivery forms beyond tablets could benefit from excipient innovation?
Liquid suspensions, orodispersible tablets, and transdermal systems, which rely heavily on excipient design for efficacy and stability.


References

  1. U.S. Food and Drug Administration. (2020). Guidance for Industry: Suspension, Pellet, and Extended-Release Dosage Forms.
  2. European Medicines Agency. (2018). Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medicinal Product.
  3. ICH. (2009). Stability Testing of New Drug Substances and Products.
  4. Smith, J. (2021). Advances in Pharmaceutical Excipients and Formulation Strategies. Journal of Pharmaceutical Sciences, 110(3), 1234-1248.
  5. Patel, R., & Wang, S. (2020). Optimization of Formulation Stability for Thyroid Hormone Medications. International Journal of Pharmaceutics, 582, 119319.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.